Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

(2018) Rona Yaeger et al.   CANCER CELL

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007

(2018) Naoise C. Synnott et al.   CANCER LETTERS

Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing

(2018) Anna K. Casasent et al.   CELL

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine

(2018) Le-Ann Hwang et al.   Cell Reports

Mutant p53 as a target for cancer treatment

(2017) Michael J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

(2017) David S. Liu et al.   Nature Communications

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

(2016) N.C. Synnott et al.   INTERNATIONAL JOURNAL OF CANCER

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

(2016) Matthias R. Bauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

(2016) George Fountzilas et al.   Oncotarget

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo

(2016) Kowthar Y. Salim et al.   Oncotarget

PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53

(2015) Mona Sobhani et al.   CANCER BIOLOGY & THERAPY

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

(2015) Lucy R Yates et al.   NATURE MEDICINE

p53 in survival, death and metabolic health: a lifeguard with a licence to kill

(2015) Flore Kruiswijk et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

(2015) Nicholas McGranahan et al.   Science Translational Medicine

Regulation of Mutant p53 Protein Expression

(2015) Reshma Vijayakumaran et al.   Frontiers in Oncology

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

(2015) Mark Kriegsmann et al.   Oncotarget

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

(2014) L. Silwal-Pandit et al.   CLINICAL CANCER RESEARCH

Mutant p53 reactivation by small molecules makes its way to the clinic

(2014) Vladimir J.N. Bykov et al.   FEBS LETTERS

Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status

(2014) Pavla Bouchalova et al.   JOURNAL OF PATHOLOGY

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome

(2013) Kelly A. Avery-Kiejda et al.   CARCINOGENESIS

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa

(2013) Manujendra N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

High frequency of complex TP53 mutations in CNS metastases from breast cancer

(2011) C Lo Nigro et al.   BRITISH JOURNAL OF CANCER

Biological functions of p53 isoforms through evolution: lessons from animal and cellular models

(2011) V Marcel et al.   CELL DEATH AND DIFFERENTIATION

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

(2011) J. F. Lara et al.   CLINICAL CANCER RESEARCH

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

(2011) Hervé Bonnefoi et al.   LANCET ONCOLOGY

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations

(2010) Henne Holstege et al.   BMC CANCER

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors

(2010) Yayun Liang et al.   BREAST CANCER RESEARCH AND TREATMENT

PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73

(2010) N Rökaeus et al.   ONCOGENE

Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution

(2009) Wenjing Zhou et al.   Molecular Oncology